About Avacta Group Plc (LON:AVCT)
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSGBX (0.09)
Return on Equity-18.76%
Return on Assets-17.83%
Frequently Asked Questions for Avacta Group Plc (LON:AVCT)
What is Avacta Group Plc's stock symbol?
Avacta Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "AVCT."
Where is Avacta Group Plc's stock going? Where will Avacta Group Plc's stock price be in 2017?
1 brokerages have issued 1 year price objectives for Avacta Group Plc's stock. Their forecasts range from GBX 160 to GBX 200. On average, they anticipate Avacta Group Plc's stock price to reach GBX 180 in the next twelve months. View Analyst Ratings for Avacta Group Plc.
Who are some of Avacta Group Plc's key competitors?
Some companies that are related to Avacta Group Plc include Applied Genetic Technologies Corporation (AGTC), Leap Therapeutics (LPTX), Inotek Pharmaceuticals Corporation (ITEK), Pfenex (PFNX), Versartis (VSAR), Aptevo Therapeutics (APVO), Rexahn Pharmaceuticals (RNN), pSivida Corp. (PSDV), Akari Therapeutics PLC (AKTX), Dipexium Pharmaceuticals (PLXP), OptiBiotix Health plc (OPTI), KemPharm (KMPH), Capricor Therapeutics (CAPR), Aradigm Corporation (ARDM), Actinium Pharmaceuticals (ATNM), Celsion Corporation (CLSN), TRACON Pharmaceuticals (TCON) and Proteostasis Therapeutics (PTI).
Who are Avacta Group Plc's key executives?
Avacta Group Plc's management team includes the folowing people:
- Alastair Smith Ph.D., Chief Executive Officer, Executive Director
- Tony Gardiner, Group Chief Financial Officer (Age 44)
- Trevor J. Nicholls Ph.D., Non-Executive Chairman of the Board (Age 58)
- Michael Scott Albin Ph.D., Non-Executive Director
- Gwyn O. Humphreys, Non-Executive Director
- Michael John Owen, Non-Executive Director (Age 64)
- Alan John Aubrey, Independent Non-Executive Director (Age 55)
How do I buy Avacta Group Plc stock?
Shares of Avacta Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Avacta Group Plc's stock price today?
One share of Avacta Group Plc stock can currently be purchased for approximately GBX 66.40.
How big of a company is Avacta Group Plc?
Avacta Group Plc has a market capitalization of £35.40 million.
How can I contact Avacta Group Plc?
Avacta Group Plc's mailing address is Unit 20, Ash Way, WETHERBY, LS23 7FA, United Kingdom. The biotechnology company can be reached via phone at +44-1904-217070.
MarketBeat Community Rating for Avacta Group Plc (AVCT)MarketBeat's community ratings are surveys of what our community members think about Avacta Group Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Avacta Group Plc (LON:AVCT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 180|
Consensus Price Target History for Avacta Group Plc (LON:AVCT)
Analysts' Ratings History for Avacta Group Plc (LON:AVCT)
(Data available from 11/24/2015 forward)
|11/21/2017||FinnCap||Reiterated Rating||Corporate||GBX 200|
|4/4/2017||Numis Securities Ltd||Reiterated Rating||Buy||GBX 160|
Earnings History for Avacta Group Plc (LON:AVCT)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Avacta Group Plc (LON:AVCT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Avacta Group Plc (LON:AVCT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Avacta Group Plc (LON AVCT)
Insider Trades by Quarter for Avacta Group Plc (LON AVCT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/21/2017||Alastair Smith||Insider||Buy||33,225||GBX 75||£24,918.75|
|7/4/2017||Michael Scott Albin||Insider||Buy||4,345||GBX 86||£3,736.70|
|4/6/2017||Michael Scott Albin||Insider||Buy||5,731||GBX 62||£3,553.22|
|10/21/2016||Mike Owen||Insider||Buy||7,763||GBX 90||£6,986.70|
|7/7/2016||Albin,Michael Scott||Insider||Buy||3,393||GBX 92||£3,121.56|
|4/29/2016||Slater ,Craig||Insider||Buy||2,222||GBX 113||£2,510.86|
|4/6/2016||Albin,Michael Scott||Insider||Buy||899||GBX 116||£1,042.84|
Latest Headlines for Avacta Group Plc (LON AVCT)
Financials are not available for this stock.
Avacta Group Plc (LON AVCT) Chart for Friday, November, 24, 2017